Vaxcyte was a private vaccine company based in San Carlos, United States. The company used advanced chemistry and a cell-free protein synthesis platform to engineer and manufacture complex vaccines. Their lead candidate is a 31-valent pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease (IPD). In 2020, Vaxcyte went public on the NASDAQ under the ticker PCVX.
Invasive pneumococcal disease
CTI LSF II
Syndicate
Observer
July 3, 2015
IPO on the NASDAQ
Series A
Vaxcyte had the best-in-class pneumococcal conjugate vaccine (PCV) for pneumococcal disease which would make Vaxcyte and attractive target for current PCV marketers.
